Traws Pharma, Inc. · NASDAQ:TRAW
Traws Pharma — Investor Presentation (June 2025)
24 slides from Traws Pharma's investor presentation, Jun 3, 2025
Slide 1: Traws Pharma - Rigosertib June 2025
Traws Pharma - Rigosertib June 2025
Slide 2: Forward-looking statements
Forward - looking statements This presentation contains, and certain oral statements made by management from time to time may contain, “forward - looking state ments” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securi
Slide 3: Rigosertib Trial Overview
Study Status Phase 3 Phase 2 Phase 1 Indication Program ISS with Thomas Jefferson University, USA and EB Haus, Austria. Study completed. RDEB - SCC Oral/IV Rigosertib Rigosertib ISS with Icahn School of Medicine, Mount Sinai. Closed for recruitment, awaiting study report. CPI Resistant KRAS - mutate
Slide 4: Introduction/Executive Summary of Rigosertib
Introduction/ Executive Summary of Rigosertib • What is Rigosertib? • How does it work – MOA? • EB and RDEB - SCC epidemiology • Rationale of Rigosertib in RDEB - SCC • RDEB - SCC clinical data so far • Clinical development plan for Rigosertib in RDEB - SCC • Clinical trial synopsis summary • Regula
Slide 5: What is Rigosertib?
What is Rigosertib? • Rigosertib sodium (ON 01910.Na; rigosertib) is the sodium salt of ( E ) - 2,4,6 - trimethoxystyryl - 3 - carboxymethylamino - 4 - methoxybenzyl sulfone, styrylbenzyl sulfones • Available as intravenous (IV) and oral formulations • Initially investigated in myelodysplastic syndr
Slide 6: Rigosertib Interferes with Multiple Signaling Pathways
Rigosertib Interferes with Multiple Signaling Pathways 6 RAS/RAF Pathway Inhibitor 1 2 3 5 6 RGS Figure adapted from Monfort - Vengut, Pharmaceutics, 2023 1: Reddy, J. Med. Chemistry, 2011 2: Athuluri - Divakar, Cell, 2016 3: Ritt, Mol. Cell, 2016 4: Atanasova, Clin. Cancer Res., 2019 5: Anderson, M
Slide 7: Epidermolysis Bullosa
Epidermolysis Bullosa • Prototypic genetic disorder of skin fragility with blisters • Mucocutaneous blistering of variable severity upon mechanical trauma • Rare: 500,000 cases worldwide (Europe 30,000, US 25 - 50,000) • 16 genes affecting structural and functional integrity of epidermis/BMZ in epit
Slide 8: What do we know about SCC in EB?
What do we know about RDEB - SCC? RDEB - SCC is the leading cause of mortality for these patients 8
Slide 9: The risk of SCC is particularly high in JEB and RDEB
The risk of SCC is particularly High in JEB and RDEB ECM, extra - cellular matrix; JEB, junctional epidermolysis bullosa; RDEB, recessive dystrophic epidermolysis bullosa; SCC, squamo us cell carcinoma TGF, transforming grown factor Bardhan A, et al. Nat Rev Dis Primers 2020;6:78 • Risks of SCC incr
Slide 10: Overall Survival of RDEB-associated SCC
Overall Survival of RDEB - associated SCC RDEB - SCC is a major cause of death for RDEB patients Fine et al J Am Acad Dermatol 2009 ; Fine et al. JAMA Dermatol. 2016; Robertson et al. Acta Derm Venereol 2021; Atanasova et al. Clin Cancer Res. 2019; Mellerio et al. British Journal of Dermatology 2016
Slide 11: High Unmet Need
Robertson et al, 2021 ; Mellerio et al, 2016 . RDEB - SCC: High Unmet Need • Predilection for boney prominences and areas of continued involvement • Poor 5 year survival • Often histologically well differentiated and benign in appearance upon initial presentation and recurrence • Currently there is
Slide 12: Rigosertib and rationale and status
Rigosertib and RDEB - SCC rationale and status 12
Slide 13: Polo-like kinase identified as a therapeutic target in RDEB cSCC
Polo - like kinase - 1 identified as a therapeutic target in RDEB c SCC Oncogene. 2011 30(46):4666 - 77. PMID: 21602893 PMCID: PMC3219832 13 Cell Death Control siRNA PLK1 siRNA
Slide 14: Rigosertib identified as lead PLK1 inhibitor in RDEB cSCC
Rigosertib identified as lead PLK1 inhibitor in RDEB cSCC Induced G2M arrest and apoptosis exclusively in RDEB - SCC keratinocytes 14
Slide 15: Rigosertib's Promising Single-agent Activity
Rigosertib’s Promising Single - agent Activity in RDEB - SCC Best response to rigosertib Prior Anticancer Treatments Rigosertib Treatment Tumor Location Age/Sex Patient ID Complete histological and cutaneous response after 12 weeks on study. 16 - month response duration. 29 prior excisions Cemiplima
Slide 16: Complete cutaneous response in the first patient treated
Rigosertib for RDEB SCC: complete cutaneous response in the first patient treated April 2021 Response duration for 16 months WCRSD 2024 Plenary presentation by Prof Andy South, and Poster presentation Laimer et al, WCRSD 2024 Prof Martin Laimer Prof Johann Bauer Salzburg, Austria 16
Slide 17: Second patient treated September 2022
Baseline 4 months 6 months Dr Neda Nikbakht Lauren Banner Thomas Jefferson, PA, USA Second patient treated September 2022 WCRSD 2024 Plenary presentation by Prof Andy South, and Poster presentation Laimer et al, WCRSD 2024 17
Slide 18: Tumor Necrosis Induced by Effective Treatment with Rigosertib
Tumor Necrosis Induced by Effective Treatment with Rigosertib Source: Austrian Rigosertib Trial, NCT03786237, as presented at ISID International Epidermolysis Bullosa Symposium/Osaka, JAP AN 2023 18 Patient AT - 01_02 TU initial (3/23) Patient AT - 01_02 TU follow up (4/23): 3 cycles Patient AT - 01
Slide 19: Fourth patient treated May 2023
Dr Neda Nikbakht Henry Yang Thomas Jefferson, PA, USA Fourth patient treated May 2023 WCRSD 2024 Plenary presentation by Prof Andy South, and Poster presentation Laimer et al, WCRSD 2024 19
Slide 20: RDEB SCC Study Highlighted in BJD publication
RDEB SCC Study Highlighted in BJD publication • 20 Laimer et al. BJD - 2024 - 2810.R1: 2025
Slide 21: RDEB SCC Study Highlighted in BJD publication
RDEB SCC Study Highlighted in in BJD publication • 21 Laimer et al. BJD - 2024 - 2810.R1: 2025
Slide 22: Trial Design
Trial Design : 2 arm multi country, multi center Phase II study Population : RDEB - SCC patients aged 12 years and above who are not candidates for surgical resection and who have failed immune checkpoint inhibitor - based therapy for SCC Treatment Arms: Treatment Arm A (Locally advanced and unresec
Slide 23: CMC: Drug Substance and Drug Product
CMC: Drug Substance and Drug Product Drug Substance: • Rigosertib DS synthesis is a 4 - step process successful at 50kg scale • Cambrex KS in Sweden and Shilpa in India have capability Drug Product: Soft G elatin Capsules (SGC), 280 mg strength, are manufactured in Ploermel France by NextPharma • Ex
Slide 24: Rigosertib Business Development Opportunity
• Traws is seeking partnership opportunities • RDEB - SCC is a de bilitating disease • RDEB - SCC is the leading cause of mortality for RDEB patients • No current approved treatments globally for RDEB - SCC • Utilizing an Investigator Sponsored Study (ISS) development strategy • 2 enrolling ISSs in